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Modulation of brain glutamate dehydrogenase as a  
tool for controlling seizures
Glutamate (Glu) is a major excitatory neurotransmitter in-
volved in epilepsy. Glu is synthesized by glutamate dehy-
drogenase (GDH, E.C. 1.4.1.3) and dysfunction of the enzy-
matic activity of GDH is associated with brain pathologies. 
The main goal of this work is to establish the role of GDH 
in the effects of antiepileptic drugs (AEDs) such as valpro-
ate (VALP), diazepam (DIAZ) and diphenylhydantoin 
(DPH) and its repercussions on oxygen consumption. Oxi-
dative deamination of Glu and reductive amination of a-
ketoglutarate (aK) in mice brain were investigated. Our 
results show that AEDs decrease GDH activity and oxygen 
consumption in vitro. In ex vivo experiments, AEDs in-
creased GDH activity but decreased oxygen consumption 
during Glu oxidative deamination. VALP and DPH re-
versed the increase in reductive amination of aK caused by 
the chemoconvulsant pentylenetetrazol. These results sug-
gest that AEDs act by modulating brain GDH activity, 
which in turn decreased oxygen consumption. GDH repre-
sents an important regulation point of neuronal excitabili-
ty, and modulation of its activity represents a potential 
target for metabolic treatment of epilepsy and for the deve-
lopment of new AEDs.
Keywords: GDH, antiepileptics, oxygen consumption, 
GABA, glutamate
The main therapeutic indication of antiepileptic drugs (AEDs) is the management of 
seizures in epileptic patients. However, they are widely used for different psychiatric in-
dications (1). However, pharmacological treatment improvements in terms of clinical out-
comes have fallen short of expectations.
Glutamate (Glu) is a major excitatory neurotransmitter and is known to be the direct 
biosynthetic precursor of gamma amino-butyric acid (GABA). Due to its neurotoxic poten-
tial, Glu may be involved in the pathogenesis of epilepsy, since it seems to play a critical 
role in the initiation and spread of seizure activity (2).
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The considerable role in epilepsy of inexcitable elements of the central nervous system 
(3–6), urges us to consider it as a disease of energy metabolism rather than neuronal dis-
charge, requiring metabolic control (7, 8). Thus, antiepileptic drugs that act on metabolic 
pathways are of great interest and should have been better studied (9). Considering epi-
lepsy from this new perspective, Glu, which participates in the control of energy homeo-
stasis, plays a dual role as it is both a signaling molecule and a metabolite at the border 
between carbohydrate and protein metabolisms.
Glutamate dehydrogenase (GDH, EC 1.4.1.3), a key enzyme in the metabolism of Glu, 
is a member of the family of enzymes that catalyze the oxidative deamination of L-Glu to 
a-ketoglutarate (aK) using nAD+ and/or nADP as coenzymes (forward reaction, Fig. 1). 
GDH also catalyzes the reductive amination of aK to Glu (reverse reaction, Fig. 1). Disor-
ders associated with GDH activity defects are restricted to the brain, suggesting that it is 
of particular importance in the biology of the central nervous system (Cns). Evidence in 
support of the participation of GDH in epilepsy includes: (i) the enzyme isolated from a 
patient with a variant form of multisystem atrophy displayed pronounced reduction of 
one of the GDH isoproteins (10); (ii) GDH activity is significantly decreased in the temporal 
cortex and hippocampus of patients with temporal lobe epilepsy (11); (iii) in patients with 
hyperinsulinism/hyperamonemia syndrome, generalized seizures may be related to ef-
fects of different GDH mutations in brain tissue (12, 13), some of them in the GTP binding 
site of GDH (14, 15); (iv) in active areas of the human epileptic cerebral cortex, GDH activ-
ity is increased (16); and (v) in focally epileptic human brain, GDH activity is increased (16). 
We have recently shown that the anticonvulsant and convulsant properties of some drugs 
are related to changes in GDH activity (17, 18).
In an attempt to explore the role of GDH in the epileptic network, we evaluated the 
effects of clinically relevant antiepileptic drugs on GDH activity and oxygen consumption 
in mouse brain using in vitro and ex vivo techniques. We hypothesize that if AEDs modify 
GDH activity, then this enzyme would represent a possible regulation point for the meta-
bolic control of epilepsy.
Knowing that convulsant drugs modify GDH activity as well as oxygen consumption 
(18), it was also investigated if AEDs could reverse seizure effects on these parameters. 
With this aim, pentylenetetrazole, a non-competitive GABA antagonist specifically used 
in seizure assays as a method of assessing the excitability of Cns and GABA activity, was 
employed.
Fig. 1. reaction catalyzed by glutamate dehydrogenase.
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Experiments were conducted in accordance with the Helsinki Guide for the Care and 
use of Laboratory Animals, adopted and promulgated by the Eu Directive 2010/63/Eu for 
animal experiments, and were approved by the institutional committee of ethics of the 
Escuela nacional de Ciencias Biológicas méxico.
Albino male mice with a mean mass of 25 g, fed ad libitum a stock laboratory diet (49.8 % 
carbohydrates, 23.5 % protein, 3.7 % fat, minerals, added vitamins and amino acids), were 
used for the experiments. The animals were maintained under a 12-h light-dark cycle.
Reagents and assays
Diazepam (DIAZ), valproic acid (VALP) and diphenylhydantoin (DPH) were pur-
chased from sigma Chemical Co. (usA).
standard analytical grade laboratory reagents were obtained from merck (Germany) 
or sigma-Aldrich Chemical Co. (usA).
Protein concentrations were determined using the Lowry method.
Brain GDH activity determination
Tissue processing. – Animals were sacrificed and whole wet brains were removed. Ho-
mogenates (25 %, m/V) were prepared with a Glas-Col tissue homogenizer in a 5 % Triton 
X-100 solution. After centrifugation at 12,500 rpm for 45 min, GDH activity was deter-
mined in the supernatant using a spectrophotometric assay according to the strecker 
method (19). Enzymatic activity assays were performed to assess Glu oxidative deamina-
tion (forward reaction) and reductive amination of aK (reverse reaction).
Oxidative deamination of glutamate. – The reaction medium contained 0.05 mol L–1 phos-
phate buffer (pH 7.6), 0.036 mol L–1 nAD and brain homogenate supernatant. The reaction 
was initiated by adding Glu (0.5 mol L–1, pH 7.0), and the absorbance at 340 nm was mea-
sured each min for five min using a spectrophotometer.
Reductive amination of a-ketoglutarate. – The reaction medium contained 0.05 mol L–1 
phosphate buffer (pH 7.6), 0.0113 mol L–1 nADH, 0.3 mol L–1 (nH4)2sO4 and brain superna-
tants. The reaction was initiated by addition of aK (0.04 mol L–1, pH 6.8) and the change in 
absorbance at 340 nm was measured each min for five min using a spectrophotometer.
Effects of selected antiepileptic drugs on brain GDH activity
In vitro effects. – Different concentrations of VALP, DPH and DIAZ (0.1 to 1 µmol L–1) 
were added to the supernatant obtained from the mouse brain homogenates. GDH activ-
ity was determined at 10, 20, 30 and 60 min after the reaction was initiated.
Ex vivo effects. – Anticonvulsant doses of VALP (170 mg kg–1), DPH (40 mg kg–1) or 
DIAZ (10 mg kg–1) were administered i.p. to groups of 5 animals. After 1 h of exposure, 
animals were sacrificed and brains were quickly removed and processed for GDH activity 
determination.
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In a separate set of experiments, animals received AEDs at the dose indicated above. 
After 1 hour of exposure, convulsions were induced via administration of pentylenetetra-
zole (PTZ, 95 mg kg–1). Twenty min later, animals were sacrificed and GDH activity was 
determined. The enzymatic activity was compared with that of animals that received only 
AEDs.
Oxygen consumption determination
Tissue processing. – Animals were sacrificed, brains were excised, and homogenates (25 
%, m/V) were prepared in 0.25 mol L–1 sucrose. The homogenate samples were centrifuged 
at 3,500 rpm for 10 minutes. The supernatants were used to determine oxygen consump-
tion using a polarographic method with a biological oxygen monitor ysI 5300 (yellow 
springs Instrumental Co., Inc. usA). Determinations were performed using the same reac-
tion medium that was used for the determination of oxidative deamination of Glu and 
reductive amination of aK catalyzed by GDH.
Effects of antiepileptic drugs on oxygen consumption
In vitro effects. – To the supernatant obtained from untreated control animals, 10, 100 
and 1,000 µmol L–1 of VALP, DPH and DIAZ were added and oxygen consumption was 
measured.
Ex vivo effects. – Groups of five animals received VALP (170 mg kg–1), DPH (40 mg 
kg–1) or DIAZ (10 mg kg–1) i.p.; the animals were sacrificed after 1 h of exposure. The brains 
were quickly removed and processed for determination of oxygen consumption.
Statistical analysis
All results were normalized against the control and expressed as the mean ± sE values 
of at least four determinations (n > 5 animals per group). GDH activity was compared be-
tween groups using a one-way analysis of variance (AnOVA), followed by Tukey’s multi-
ple comparison test. Differences with p value < of 0.05 were considered statistically sig-
nificant.
rEsuLTs AnD DIsCussIOn
Despite its wide use, the mechanisms of VALP action are not fully understood. The 
results shown in Fig. 2 suggest that VALP may act by modifying GDH activity, since de-
creased activity was observed in Glu oxidative deamination as well as in reductive amina-
tion of aK in vitro.
results described herein indicate that DPH also influences GDH activity by decreas-
ing reductive amination of aK after 60 minutes of incubation (Fig. 2a) and Glu oxidative 
deamination (Fig. 2b). Considering that DPH prevents the spread of seizure activity by 
stabilizing the neuronal membrane, a minor effect of DPH on GDH activity in vitro was 
expected, since convulsive activity was not induced in these experiments.
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Fig. 2. In vitro effects of selected antiepileptic drugs on mouse brain glutamate dehydrogenase activ-
ity. results are presented as the mean + sEm (n > 4). An AnOVA test was applied, and the asterisk (*) 
indicates statistically different groups compared to the control (p < 0.05, Tukey’s test). a) reductive 
amination of a ketoglutarate (a ketoglutarate           L-glutamate); b) Oxidative deamination of L-glu-
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results in Fig. 2 also demonstrated that decreased GDH activity observed after the 
treatment with DIAZ may be related to its antiepileptic properties.
When Glu was used as the substrate for oxidative deamination by GDH, the results 
demonstrated that all AEDs assayed decreased GDH activity (Fig. 2b). This is important 
because it would lead to accumulation of Glu in the system. This additional Glu may be 
used as substrate for GABA synthesis.
The AEDs tested affected GDH activity not only in vitro but also ex vivo, since the 
evaluation showed that exposure to AEDs slightly but significantly modified aK reductive 
amination. DPH increased GDH activity whereas VALP and DIAZ treatment decreased 
GDH activity (Fig. 3a). Contrary to the results observed in vitro (with the exception of 
DIAZ), AEDs increased the oxidative deamination of Glu, as shown in Fig. 3b. It is plau-
sible that the main cause of the differences observed between the in vitro and ex vivo results 
are due to differences in brain energy requirements, i.e., metabolic regulation influenced 
ex vivo GDH activity.
Previous results obtained with convulsant drugs (18) support the hypothesis that 
GDH participates in the initiation of seizures and that the inhibition of GDH activity may 
constitute one of the many possible mechanisms of action of these drugs. If these hypoth-
eses are correct, an increase in Glu utilization by GDH would lead to decreased Glu levels, 
causing low neuronal excitability, which may contribute to the antiepileptic properties of 
VALP and DPH. Experiments analyzing the role of GDH in the protective effects induced 
by AEDs on seizures caused by PTZ exposure revealed several interesting findings that 
support these hypotheses (Fig. 4). Firstly, PTZ increased GDH activity by approximately 
20 % when aK was used as a substrate (Fig. 4a), but the enhanced GDH activity induced 
by exposure to the convulsant was reversed by AEDs, with GDH activity returning to 
levels lower than those observed in the control group (Fig. 4a). secondly, PTZ produced no 
effect when Glu was used as substrate, whereas VALP and DPH treatment increased Glu 
oxidative deamination in the presence of seizures induced by PTZ, whereas DIAZ had no 
effect on PTZ exposure (Fig. 4b).
Fig. 3. Ex vivo effects of select antiepileptic drugs on mouse brain glutamate dehydrogenase activity. 
results are presented as the mean + sEm (n > 4). * denotes statistically significant differences com-
pared to the control (p < 0.05 student’s t test). a) reductive amination of a-ketoglutarate (a-k) a-keto-
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reversion of PTZ effect on aK reductive amination caused by AEDs, with GDH activ-
ity to levels lower than those observed in the control group (20 to 30 %, Fig. 4a), would 
result in decreased Glu levels. On the other hand, though PTZ exposure decreased the 
oxidative deamination of Glu by 15 to 30 % in animals previously protected by VAL or 
DPH treatment, GDH activity was still increased when compared to the control group. 
Thus, AEDs treatment shifted the equilibrium of the GDH reaction to oxidative deamina-
tion of Glu, which reduced Glu levels and neuronal excitability.
The effect of AEDs on oxygen consumption in brain supernatants (highly enriched in 
mitochondria) was dependent on the substrate used. When aK reductive amination was 
catalyzed by GDH, all AEDs diminished oxygen consumption (Fig. 5a). During oxidative 
Fig. 4. Influence of pentylenetetrazole on ex vivo effects of selected antiepileptic drugs on mouse brain 
glutamate dehydrogenase activity. results are presented as the mean + sEm (n > 4) and were com-
pared with those of animals that received only the corresponding antiepileptic. An AnOVA test was 
applied and an asterisk (*) is used to indicate statistically different groups compared to the control (p 
< 0.05, Tukey’s test). a) reductive amination of a-ketoglutarate (a-k) a-ketoglutarate           L-glutamate; 





Fig. 5. In vitro effects of selected antiepileptic drugs on oxygen consumption. results are presented as 
the mean + sEm (n > 4). An AnOVA test was applied, and an asterisk (*) was used to indicate statisti-
cally different groups compared to the control (p < 0.05, Tukey’s test). a) reductive amination of a-
ketoglutarate (a-k) a-ketoglutarate           L-glutamate; b) Oxidative deamination of L-glu tamate (L-glu) 
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deamination of Glu, oxygen consumption also decreased, but only in case of high concen-
trations (1 mmol L–1) of AEDs, the highest concentration of AEDs tested in vitro (Fig. 5b).
The decreased oxygen consumption in vitro caused by AEDs when reductive amina-
tion of aK was catalyzed by GDH (Fig. 5a), indicates diminished brain metabolic activity. 
Because additional energy was not required under these conditions, generation of aK was 
unnecessary. This could explain the decrease of GDH activity observed when Glu was 
used as the substrate (Fig. 2b).
Ex vivo, with the exception of VALP, AEDs did not modify oxygen consumption when 
aK was used as substrate for GDH (Fig. 6a), but all of them decreased oxygen consumption 
when oxidative deamination of Glu was catalyzed by GDH (Fig. 6b). These results imply 
that aK generated by the high GDH activity under these conditions was not introduced to 
the TCA cycle because metabolic activity was not required.
Fig. 6. Ex vivo effects of selected antiepileptic drugs on oxygen consumption. results are presented as 
the mean + sEm (n > 4). * denotes statistically significant differences compared to the control (p < 0.05, 
student’s t test). a) reductive amination of a-ketoglutarate (a-k) a-ketoglutarate           L-glutamate; b) 





In accordance with previous findings, our hypothesis that GDH participates in the 
mechanism of the initiation of seizures is supported by the data presented herein. In a 
previous work, we demonstrated that anticonvulsants such as pyridoxal phosphate, ami-
nooxyacetic acid and hydroxylamine modify GDH activity in vitro, with apparent linkage 
to changes in oxygen consumption (17), just like antiepileptic drugs of broad clinical use 
tested herein. Described effects of anticonvulsants and antiepileptic drugs tested on GDH 
activity could decrease the Glu levels but also diminish oxygen consumption ex vivo when 
Glu oxidative deamination was catalyzed by GDH. It must be realized that effects of AEDs 
on GDH activity and oxygen consumption are opposite to those previously reported for 
chemoconvulsants such as pentylenetetrazole, thiosemicarbazide and bicuculline (18).
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Overall, the results presented here suggest that VALP, DPH and DIAZ share a com-
mon and not yet described target: GDH. Treatment with these AEDs could modulate GDH 
activity, which induced concomitant changes in oxygen consumption. Clearly, GDH rep-
resents an important regulation point of brain Glu and GABA levels and thus contributes 
to the regulation of neuronal excitability. We propose a new mechanism for the metabolic 
treatment of epilepsy: modulation of GDH activity, as observed in mouse brain.
Abbreviations, acronyms, symbols. – AEDs – antiepileptic drugs, Glu – glutamate, Cns – central ner-
vous system, aK – a-ketoglutarate, DIAZ – diazepam, nAD(H) – nicotinamide adenine dinucleotide, 
AEDs – diphenylhydantoin, PTZ – pentylenetetrazole, GABA – gamma amino-butyric acid, VALP – 
valproate, GDH – glutamate dehydrogenase, TCA – tricarboxylic acid cycle.
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